# Targeting Orexin to Treat Nicotine Dependence

> **NCT03999099** · PHASE1 · UNKNOWN · sponsor: **Mclean Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Nicotine Dependence

## Interventions

- **DRUG:** Suvorexant 20 mg
- **DRUG:** Suvorexant 10 mg
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT03999099
- **Lead sponsor:** Mclean Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-26
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03999099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03999099, "Targeting Orexin to Treat Nicotine Dependence". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03999099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*